Nasdaq Amex NYSE Reverse Splits

[deadjim]

$VVUS 1 for 10::

[starbuxsux]

Press Release: Tiger Media Announces Completion of One-for-Five Reverse Stock Split and Domestication as a Delaware Corporation

9:00 AM ET 3/20/15 | Dow Jones

Tiger Media Announces Completion of One-for-Five Reverse Stock Split and Domestication as a Delaware Corporation SHANGHAI--(BUSINESS WIRE)--March 20, 2015--

Tiger Media, Inc. ("Tiger Media" or the "Company") (NYSE MKT: IDI), a Shanghai-based multi-platform media company, announced today that the previously approved reverse stock split of the Company's ordinary shares, par value $0.0001 per share, at a ratio of one-for-five (the "Stock Split"), became effective after the close of business on March 19, 2015. The Company's common stock will begin trading on a split-adjusted basis at the open of business on the morning of March 20, 2015. The Company's common stock will continue to trade on the NYSE MKT under the symbol IDI with a new CUSIP of 88674Y 105. The ability to trade in the Company's common stock should be unaffected by the Stock Split. Also, the Company announced the completion of its domestication as a Delaware corporation (the "Domestication"), effective before the open of business on March 20, 2015. The Company expects to complete the previously announced acquisition of The Best One, Inc. after the close of business on Friday.

About Tiger Media, Inc.

Tiger Media is a leading Shanghai-based multi-platform media company in China which provides advertising services in the out-of-home advertising industry, including iScreen Outdoor LCD screens, billboards and street furniture. Tiger Media's network of street level LCD screen displays, which captivate eye-level awareness, is complemented by outdoor billboards which are mostly built on rooftops with good visibility from far distances. Tiger Media's network attracts advertising clients from a wide range of industries including telecommunications, insurance and banking, automobile, electronics and fast moving consumer goods. Learn more at www.tigermedia.com.

FORWARD LOOKING STATEMENTS

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipate," "believes," "should," "intends," "estimates," and other words of similar meaning. Such forward looking statements include statements about the expected completion of the Merger. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: the ability of each of Tiger Media and TBO to satisfy the closing conditions and consummate the transaction, and the other risks set forth in Tiger Media's Annual Report on Form 20-F, filed with the SEC on March 31, 2014, and Tiger Media's proxy statement for the Special Meeting of Ordinary Shareholders held on March 17, 2015, filed with the SEC on February 13, 2015, as well as the other factors described in the filings that Tiger Media makes with the SEC from time to time.

The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.

CONTACT: Tiger Media, Inc.

Investor Relations:

Joshua Weingard, 305-575-4602

[e-mail]



> Dow Jones Newswires

March 20, 2015 09:00 ET (13:00 GMT)

[donwillems]

24/2/2015 SLTD 1:26 R/S for uplisting to NYSE/NASDAQ

Solar3D Completes Reverse Stock Split

Company Takes Key Step in Preparation for Uplisting onto Senior Exchange

SANTA BARBARA, CA--- February 24, 2015 - Solar3D, Inc. (SLTD) (SLTDD), a leading provider of solar solutions and the developer of a proprietary high efficiency solar cell, is pleased to announce that it has effected a 1-for-26 reverse split of its issued and outstanding common stock (the "Reverse Split”) which will be effective February 25, 2015, as a key step in preparation for uplisting of the Company’s common shares onto a senior exchange.

Jim Nelson, CEO of Solar 3D said, “The reverse stock split was implemented to meet the price requirements for uplisting onto a senior exchange. Our Board and shareholders have strongly supported this initiative, as it will help broaden our shareholder base and improve liquidity in our common stock. We look forward to moving quickly towards this goal.”

As of the market open tomorrow, the Company’s shares will trade under the symbol “SLTDD,” with a “D” added for 20 trading days to signify that the reverse stock split has occurred. A new CUSIP number (83417A209) has been assigned to the Company’s common stock as a result of the reverse split.

As a result of the Reverse Split, the total issued and outstanding common shares will be reduced from approximately 381.7 million shares to approximately 14.7 million, subject to adjustment for fractional shares. No fractional shares are to be issued.

Any fractional shares resulting from the reverse stock split will be rounded up to the nearest whole share. The number of shares of common stock underlying the options, warrants, convertible securities or other rights to acquire shares of common stock will be adjusted accordingly.


About Solar3D, Inc.

Solar3D is a leading provider of solar power solutions and the developer of a proprietary high efficiency solar cell. The company’s SUNworks division focuses on the design, installation and management of solar power systems for commercial, agricultural and residential customers. SUNworks is one of the fastest growing solar systems providers in California and has delivered hundreds of 2.5 kilowatt to 1-megawatt commercial systems and has the capability of providing systems as large as 25 megawatts. Solar3D’s technology division is developing a patent-pending 3-dimensional solar cell technology to maximize the conversion of sunlight into electricity. The Solar3D Cell collects sunlight from a wide angle and lets light bounce around in 3-dimensional microstructures on the solar cell surface. The Company’s mission is to further the widespread adoption of solar power by deploying affordable, state-of-the-art systems and developing breakthrough new solar technologies.

To learn more about Solar3D, visit our website at www.solar3d.com .

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These risks include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, products, and prospects for sales, failure to commercialize our technology, failure of technology to perform as expected, failure to earn profit or revenue, higher costs than expected, persistent operating losses, ownership dilution, inability to repay debt, failure of acquired businesses to perform as expected, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

[donwillems]

SLTD will do a 25 to 45 reverse split to uplist to nasdaq/nyse
Will this be any good? Thoughts on this anyone?
they are profitable

[$tockfather]

CHOP- Board of Directors Approve of One-for-Ten Reverse Stock Split

On November 6, 2014, the Company's Board of Directors approved a one-for-ten reverse stock split of the Company's issued and outstanding Ordinary Shares. It is expected that the Company's Ordinary Shares will begin trading on the NASDAQ Stock Market on a split-adjusted basis when the market opens on November 7, 2014. The Company's Ordinary Shares will continue to trade under the symbol "CHOP" but with a new CUSIP number.

The reverse stock split is intended to increase the per share trading price of the Company's Ordinary Shares to satisfy the $1.00 minimum bid price requirement for continued listing on the NASDAQ Stock Market.

As a result of the reverse stock split, every 10 issued and outstanding shares at the effective time will automatically be combined into one issued and outstanding share without any change in par value of those shares. In lieu of issuing fractional shares, the Company will round fractions of shares up to the nearest whole share.

Once the reverse stock split becomes effective, stockholders holding shares through a brokerage account or held in "street name" will have their shares automatically adjusted to reflect the 1-for-10 reverse stock split. Existing stockholders holding certificates of Ordinary Shares will receive a letter of transmittal from the Company's transfer agent, Continental Stock Transfer & Trust, with specific instructions regarding the exchange of shares. All outstanding stock options, warrants and other rights to purchase the Company's Ordinary Shares will be adjusted proportionately as a result of the reverse stock split. This will reduce the number of outstanding Ordinary Shares of the Company from approximately 59.3 million to approximately 5.9 million. However, the number of total authorized Ordinary Shares of the Company will not be changed as a result of the reverse split. Please direct any questions to your broker or the Company's Transfer Agent, Continental Stock Transfer & Trust, by calling 212-845-3277.

[deadjim]

saw that. nice calls, both directions

[hebercreeper]

$INVE time for dump?

[deadjim]

$MCOX lift attempt

[deadjim]

$BONE erection

[deadjim]

$IVAN

[deadjim]

$BONE

[deadjim]

$OCFN

[deadjim]

$DMD

[deadjim]

$VBFC

[deadjim]

$SNBC

[deadjim]

$APH

[deadjim]

$RKT

[deadjim]

$NCT

[deadjim]

$EMITF

[deadjim]

$ASTI

[deadjim]

plenty of recent splits in play. I'm sure you've seen a few. need to auto the charts. ill post em this weekend or just look at days gainers, ha

[deadjim]

I saw that.. It's slow though - I wouldn't know how to trade it, other than get lucky, sit on it, and pray every night. ha

[hebercreeper]

INVE some move since the R/S there

[wendy fox]

$BONE just split 1:10 today. I'll try to post chart

[deadjim]

$INVE 1:10




http://finance.yahoo.com/q/ks?s=INVE+Key+Statistics
http://www.otcmarkets.com/stock/INVE/filings

[starbuxsux]

$INO - Inovio Pharmaceuticals Announces 1 For 4 Reverse Split

May 23, 2014 04:00:00 (ET)

BLUE BELL, Pa., May 23, 2014 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today announced that at the Company's Annual General Meeting held May 22, 2014, the Company's shareholders approved the proposal of a reverse split of the Company's common stock. The Company's Board of Directors subsequently approved the immediate implementation of a 1-for-4 reverse stock split of Inovio's common stock, where each 4 shares of issued and outstanding common stock and equivalents will be converted into 1 share of common stock. Following standard NYSE administrative processes, the Company plans to announce at a later time the effective date of the reverse split.

Dr. J. Joseph Kim, President and CEO, said, "I thank our shareholders for their support of Inovio. We would not be where we are today without their belief in our team and the potential of our DNA immunotherapies to treat cancers and infectious diseases. Our company has never been stronger in terms of its technology, product pipeline, preclinical and clinical data, collaborations, capital and operating runway. Our stockholders approved a reverse split to have our price and share structure reflect our leadership position in immunotherapies and expand our potential investor audience. We look forward to our upcoming milestones and will continue to focus on advancing our SynCon(R) immunotherapies with the goals of commercializing clinically important products, achieving fundamental growth, and rewarding our investors."

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon(R) vaccines, in combination with its proprietary electroporation delivery, are generating best-in-class immune responses, with therapeutic T-cell responses exceeding other technologies in terms of magnitude, breadth, and response rate. Human data to date have shown a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused pre-cancers and cancers, is in phase II. Other phase I and preclinical programs target prostate, breast, and lung cancers as well as HIV, influenza, malaria and hepatitis. Partners and collaborators include Roche, the University of Pennsylvania, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, University of Southampton, US Dept. of Homeland Security, University of Manitoba. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2013, our Form 10-Q for the quarter ended March 31, 2014, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:

Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, [e-mail]

Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, [e-mail]

Logo - http://photos.prnewswire.com/prnh/20131118/LA18202LOGO

SOURCE Inovio Pharmaceuticals, Inc.

/Web site: http://www.inovio.com


(END) Dow Jones Newswires

May 23, 2014 04:00 ET (08:00 GMT)

[deadjim]

thanks. please post chart if adding a symbol to board. thanks for posting. the more eyes the better we find then

[wendy fox]

Missed $SNV May 19 1:7 and $TRXC Apr 2 1:5

[wendy fox]

$NEWL just reverse split again 1:50

[deadjim]

$DCTH 1:16



http://finance.yahoo.com/q/ks?s=DCTH+Key+Statistics
http://www.otcmarkets.com/stock/DCTH/filings

[deadjim]

not sure

[wendy fox]

Why so few reverse splits late?

[deadjim]

$NEWL 1:10 .. which makes how many splits now? ha

[deadjim]

$DARA news.. so annoying when they gap like that and I'm not in

[wendy fox]

Great entry time for CVM

[deadjim]

$DARA 1:10





http://finance.yahoo.com/q/ks?s=DARA+Key+Statistics
http://www.otcmarkets.com/stock/DARA/filings

[carp1]

DARA I'm a buyer when the dust settles! http://finance.yahoo.com/news/dara-biosciences-announces-1-5-130000988.html

[wendy fox]

DARA to reverse split Feb 10

[deadjim]

yep, trying to get back on the Nasd

[starbuxsux]

$LJPCD

[deadjim]

Everybody who keeps track of the post R/S plays I hope nailed FREE and NEWL. For updates on what we're playing, check the best Ihub board around: GoodFellas http://investorshub.advfn.com/GoodFellas-Big-Boards-Stock-Plays-23057/

[deadjim]

$TCX 1:4



http://finance.yahoo.com/q/ks?s=TCX+Key+Statistics
http://www.otcmarkets.com/stock/TCX/filings

[deadjim]

$FMD 1:10



http://finance.yahoo.com/q/ks?s=FMD+Key+Statistics
http://www.otcmarkets.com/stock/FMD/filings

[cybersync]

FREE@NASDAQ (Name: FREESEAS INC) announced a reverse split effective 20131202. The terms of the split are 1 : 5.

[deadjim]

$NEWL 1:3


saw chatter about seller being gone. but might still be some warrants left.
either way, radar it, has nice range down in here.


PIRAEUS, Greece, Nov. 20, 2013 /PRNewswire/ -- NewLead Holdings Ltd. (NASDAQ: NEWL) ("NewLead" or the "Company") today announced that a 1-for-3 reverse stock split of its common shares has been approved by the Company's Board of Directors and by written consent of a majority of shareholders, effective upon the commencement of trading on December 6, 2013.

[deadjim]

CURRENT SPLIT LIST
Alphabetical order

If I missed any let me know and I'll update.


2013-11-14-Reverse_Split_Stocks



$ABIOMore
$AEZSMore
$ALTIMore
$ALVRMore
$ANIPMore
$ANTHMore
$ASTMMore
$BIOFMore
$BOSCMore
$BPAXMore
$BWENMore
$BXMTMore
$CADCMore
$CBRXMore
$CLWTMore
$CPSLMore
$CTMore
$CXMMore
$CYCCMore
$CYTKMore
$DHTMore
$DRLMore
$DYNTMore
$EBODMore
$ECTEMore
$EGTMore
$FBNMore
$FREEMore
$FUMore
$ICLDMore
$IGCMore
$IVANMore
$JASOMore
$JAXBMore
$MCOXMore
$MEIPMore
$MOTRMore
$MRVCMore
$NBSMore
$NEWLMore
$NTWKMore
$NWBOMore
$OCLSMore
$OCRXMore
$OPXAMore
$OXBTMore
$PEIXMore
$PESIMore
$PGRXMore
$PULSMore
$QTWWMore
$RNINMore
$RXIIMore
$SCONMore
$SPPRMore
$SRMore
$STXSMore
$SYNMMore
$URREMore
$USUMore
$UTSIMore
$VISNMore
$VLTCMore
$VSCPMore
$WPCSMore
$ZBBMore
$ZLCSMore
$ZOOMMore

[carp1]

JAXB Post split moving nicely!! Chart

[$tockfather]

ZOOM- Well that didn't take long. Up 35% and is Nasdaq #2 percentage gainer today...

[$tockfather]

ZOOM- 1:10 R/S

Zoom Technologies, Inc.'s (the "Company") Certificate of Amendment (the "Certificate") became effective with the Secretary of State of Delaware on November 11, 2013 (the "Amendment"). As a result of the Amendment, the Company's outstanding shares of common stock were split at a ratio of 1 for 10 (the "Reverse Split"). Upon effectiveness of the Reverse Split, the Company's issued and outstanding shares of common stock were decreased from 30,086,848 to 3,008,685 shares of common stock, all with a par value of $0.01. Fractional shares resulting from the Reverse Split were rounded up to the next whole number. The Reverse Split did not affect the number of shares of common stock that the Company is authorized to issue. The split-adjusted shares of the Company's common stock will begin trading on the Nasdaq Capital Market on Tuesday, November 12, 2013 under the same symbol ("ZOOM").

[deadjim]

$LIME 1:7



http://finance.yahoo.com/q/ks?s=LIME+Key+Statistics
http://www.otcmarkets.com/stock/LIME/filings